REGN FY 2013 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$80B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.1B+52.7% YoY

Gross Profit

$1.9B90.7% margin

Operating Income

$743M35.3% margin

Net Income

$424M20.2% margin

EPS (Diluted)

$3.72

Cash Flow

Operating Cash Flow

$589M

Free Cash Flow

$432M

Stock-Based Comp.

$198M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$999M

Stockholders' Equity

$2.0B

Cash & Equivalents

$536M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.1B	$1.4B	+52.7%
Gross Profit	$1.9B	$1.3B	+51.8%
Operating Income	$743M	$461M	+61.4%
Net Income	$424M	$750M	-43.4%